Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02034188 (ClinicalTrials.gov)	January 2014	9/1/2014	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: Umbilical cord mesenchymal stem cells	Translational Biosciences	NULL	Completed	18 Years	55 Years	All	20	Phase 1/Phase 2	Panama
2	NCT01364246 (ClinicalTrials.gov)	January 2010	31/5/2011	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Progressive Multiple Sclerosis;Neuromyelitis Optica.	Biological: human umbilical cord mesenchymal stem cells	Shenzhen Beike Bio-Technology Co., Ltd.	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical University	Recruiting	18 Years	60 Years	Both	20	Phase 1/Phase 2	China